Ramesh Paudyal

Objectives: There is a growing need to develop user-friendly, bladder-specific image analysis tools that can produce reliable artificial intelligence (AI)-quantitative imaging biomarkers (QIBs) derived from multiparametric (mp)MRI data for clinical applications. To address it, we developed an AI-powered BLADdEr multiparametric MRI Analysis for Clinical Application (AI-BLADE, current release v1.0) toolbox designed for extracting mpMRI-derived quantitative metrics. Methods: AI-BLADE is an advanced tool for bladder-specific mpMRI data analysis with 2 core functionalities: (1) Deep Feature Analysis (MRI-DFA toolkit) and (2) Data-Driven Model-Based Analysis (MRI-MBA toolkit). AI-BLADE offers customizable options and serves as a one-stop shop solution for bladder cancer (BCa) clinical applications. The models within DFA and MBA were tested separately on 2 patient cohorts. DFA was used to classify BCa histology subtypes (n = 104) with T2-weighted images, while MBA was used to interrogate tumour physiology by deriving mpMRI QIBs, including apparent diffusion coefficient (ADC), and volume transfer constant (Ktrans) obtained from 34 BCa patients. Results: Out of the 17 AI models tested, the VGG19 model with a decision tree classifier and no feature selection for the fully connected layer 7 achieved the highest area under the curve of the receiver operating characteristic of 0.79 in classifying BCa histology subtypes, demonstrating the strongest performance. The mean ADC and Ktrans values were 1.22 × 10−3 (mm2/s) and 0.27 (min−1), respectively, reflecting underlying tumour physiology. Conclusion: The AI-BLADE (v1.0), a flexible and user-friendly software toolbox for analysing mpMRI data, shows strong potential for application in BCa oncology, offering capabilities that can enhance diagnostic accuracy and support improved patient outcomes. Advances in knowledge: This is the first study to design, develop, and implement a novel bladder-specific AI toolbox for analysing mpMRI data. AI-BLADE enables an advanced image analysis workflow, facilitating AI-QIB-based clinical decision-making for patients with BCa.

Background/Objectives: The tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) is characterized by an enriched stroma, hampering the effectiveness of therapy. This co-clinical study aimed to (1) provide insight into early post-treatment changes in the TME using multiparametric magnetic resonance imaging (mpMRI)-derived quantitative imaging biomarkers (QIBs) in a preclinical PDAC model treated with radiotherapy and correlate these QIBs with histology; (2) evaluate the feasibility of obtaining these QIBs in patients with PDAC using clinically approved mpMRI data acquisitions. Methods: Athymic mice (n = 12) at pre- and post-treatment as well as patients with PDAC (n = 11) at pre-treatment underwent mpMRI including diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) data acquisition sequences. DW and DCE data were analyzed using monoexponential and extended Tofts models, respectively. DeepLIIF quantified the total percentage (%) of tumor cells in hematoxylin and eosin (H&E)-stained tissues from athymic mice. Spearman correlation and Wilcoxon signed rank tests were performed for statistical analysis. Results: In the preclinical PDAC model, mean pre- and post-treatment ADC and K^trans values differed significantly (p < 0.01), changing by 20.50% and 20.41%, respectively, and the median total tumor cells quantified by DeepLIIF was 24% (range: 15–53%). Post-treatment ADC values and relative change in v_e (rΔv_e) showed a significant negative correlation with total tumor cells (ρ = −0.77, p < 0.014 for ADC and ρ = −0.77, p = 0.009 for rΔv_e). In patients with PDAC, pre-treatment mean ADC and K^trans values were 1.76 × 10⁻³ (mm²/s) and 0.24 (min⁻¹), respectively. Conclusions: QIBs in both preclinical and clinical settings underscore their potential for future co-clinical research to evaluate emerging drug combinations targeting both tumor and stroma.

Background/Objectives: This work prospectively evaluates the vendor-provided Low Variance (LOVA) apparent diffusion coefficient (ADC) gradient nonlinearity correction (GNC) technique for primary tumors, neck nodal metastases, and normal masseter muscles in patients with head and neck cancers (HNCs). Methods: Multiple b-value diffusion-weighted (DW)-MR images were acquired on a 3.0 T scanner using a single-shot echo planar imaging (SS-EPI) and multi-shot (MS)-EPI for diffusion phantom materials (20% and 40% polyvinylpyrrolidone (PVP) in water). Pretreatment DW-MRI acquisitions were performed for sixty HNC patients (n = 60) who underwent chemoradiation therapy. ADC values with and without GNC were calculated offline using a monoexponential diffusion model over all b-values, relative percentage (r%) changes (Δ) in ADC values with and without GNC were calculated, and the ADC histograms were analyzed. Results: Mean ADC values calculated using SS-EPI DW data with and without GNC differed by ≤1% for both PVP20% and PVP40% at the isocenter, whereas off-center differences were ≤19.6% for both concentrations. A similar trend was observed for these materials with MS-EPI. In patients, the mean rΔADC (%) values measured with SS-EPI differed by 4.77%, 3.98%, and 5.68% for primary tumors, metastatic nodes, and masseter muscle. MS-EPI exhibited a similar result with 5.56%, 3.95%, and 4.85%, respectively. Conclusions: This study showed that the GNC method improves the robustness of the ADC measurement, enhancing its value as a quantitative imaging biomarker used in HNC clinical trials.

Objectives: This study aims to evaluate the impact of image preprocessing methods, including traditional and artificial intelligence (AI)-based techniques, on the performance of MRI-based radiomics for predicting tumour aggressiveness in papillary thyroid carcinoma (PTC). Methods: We retrospectively analysed MRI data from 69 patients with PTC, acquired between January 2011 and April 2023, alongside corresponding histopathology. MRI scans underwent N4 bias field correction and resampling using 10 traditional methods and an AI-based technique, synthetic multi-orientation resolution enhancement (SMORE). Radiomic features were extracted from the original and preprocessed images. Recursive feature elimination with random forests was used for feature selection, and predictive models were developed using XGBoost. The performance of the model was assessed by calculating the area under the receiver operating characteristic curve (AUC) across 1000 iterations. Results: The combination of the correction of the bias field of N4 with SMORE resampling produced the highest mean AUC (0.75), significantly outperforming all traditional resampling methods (P<.001). The lowest mean AUC (0.66) was observed with nearest neighbour resampling. Texture-based radiomic features, particularly the standard deviation of the grey-level co-occurrence matrix autocorrelation, were frequently selected in models using SMORE-resampled images. Conclusions: Preprocessing techniques critically influence the predictive performance of MRI-based radiomics in PTC. The combination of N4 bias field correction and SMORE resampling enhances accuracy, highlighting the necessity of optimizing preprocessing pipelines. Advances in knowledge: This study demonstrates the superiority of AI-driven preprocessing techniques, such as SMORE, in improving MRI radiomic models, paving the way for enhanced clinical decision-making in PTC management.

PURPOSE: Standard curative-intent chemoradiotherapy for human papillomavirus (HPV)–related oropharyngeal carcinoma results in significant toxicity. Since hypoxic tumors are radioresistant, we posited that the aerobic state of a tumor could identify patients eligible for de-escalation of chemoradiotherapy while maintaining treatment efficacy. METHODS: We enrolled patients with HPV-related oropharyngeal carcinoma to receive de-escalated definitive chemoradiotherapy in a phase II study (ClinicalTrials.gov identifier: NCT03323463 ). Patients first underwent surgical removal of disease at their primary site, but not of gross disease in the neck. A baseline ¹⁸F-fluoromisonidazole positron emission tomography scan was used to measure tumor hypoxia and was repeated 1-2 weeks intratreatment. Patients with nonhypoxic tumors received 30 Gy (3 weeks) with chemotherapy, whereas those with hypoxic tumors received standard chemoradiotherapy to 70 Gy (7 weeks). The primary objective was achieving a 2-year locoregional control (LRC) of 95% with a 7% noninferiority margin. RESULTS: One hundred fifty-eight patients with T0-2/N1-N2c were enrolled, of which 152 patients were eligible for analyses. Of these, 128 patients met criteria for 30 Gy and 24 patients received 70 Gy. The 2-year LRC was 94.7% (95% CI, 89.8 to 97.7), meeting our primary objective. With a median follow-up time of 38.3 (range, 22.1-58.4) months, the 2-year progression-free survival (PFS) and overall survival (OS) rates were 94% and 100%, respectively, for the 30-Gy cohort. The 70-Gy cohort had similar 2-year PFS and OS rates at 96% and 96%, respectively. Acute grade 3-4 adverse events were more common in 70 Gy versus 30 Gy (58.3% v 32%; P = .02). Late grade 3-4 adverse events only occurred in the 70-Gy cohort, in which 4.5% complained of late dysphagia. CONCLUSION: Tumor hypoxia is a promising approach to direct dosing of curative-intent chemoradiotherapy for HPV-related carcinomas with preserved efficacy and substantially reduced toxicity that requires further investigation.

Auto-segmentation promises greater speed and lower inter-reader variability than manual segmentations in radiation oncology clinical practice. This study aims to implement and evaluate the accuracy of the auto-segmentation algorithm, “Masked Image modeling using the vision Transformers (SMIT),” for neck nodal metastases on longitudinal T₂-weighted (T₂w) MR images in oropharyngeal squamous cell carcinoma (OPSCC) patients. This prospective clinical trial study included 123 human papillomaviruses (HPV-positive [+]) related OSPCC patients who received concurrent chemoradiotherapy. T₂w MR images were acquired on 3 T at pre-treatment (Tx), week 0, and intra-Tx weeks (1-3). Manual delineations of metastatic neck nodes from 123 OPSCC patients were used for the SMIT auto-segmentation, and total tumor volumes were calculated. Standard statistical analyses compared contour volumes from SMIT vs manual segmentation (Wilcoxon signed-rank test [WSRT]), and Spearman’s rank correlation coefficients (ρ) were computed. Segmentation accuracy was evaluated on the test data set using the dice similarity coefficient (DSC) metric value. P-values 3, P = 0.26 [WSRT]), and the Bland-Altman method established the limits of agreement as –1.71 to 2.31 cm³, with a mean difference of 0.30 cm³. SMIT model and manually delineated tumor volume estimates were highly correlated (ρ = 0.84-0.96, P < 0.001). The mean DSC metric values were 0.86, 0.85, 0.77, and 0.79 at the pre-Tx and intra-Tx weeks (1-3), respectively. The SMIT algorithm provides sufficient segmentation accuracy for oncological applications in HPV+ OPSCC. First evaluation of auto-segmentation with SMIT using longitudinal T₂w MRI in HPV+ OPSCC.

This review focuses on the principles, applications, and performance of mpMRI for bladder imaging. Quantitative imaging biomarkers (QIBs) derived from mpMRI are increasingly used in oncological applications, including tumor staging, prognosis, and assessment of treatment response. To standardize mpMRI acquisition and interpretation, an expert panel developed the Vesical Imaging–Reporting and Data System (VI-RADS). Many studies confirm the standardization and high degree of inter-reader agreement to discriminate muscle invasiveness in bladder cancer, supporting VI-RADS implementation in routine clinical practice. The standard MRI sequences for VI-RADS scoring are anatomical imaging, including T₂w images, and physiological imaging with diffusion-weighted MRI (DW-MRI) and dynamic contrast-enhanced MRI (DCE-MRI). Physiological QIBs derived from analysis of DW- and DCE-MRI data and radiomic image features extracted from mpMRI images play an important role in bladder cancer. The current development of AI tools for analyzing mpMRI data and their potential impact on bladder imaging are surveyed. AI architectures are often implemented based on convolutional neural networks (CNNs), focusing on narrow/specific tasks. The application of AI can substantially impact bladder imaging clinical workflows; for example, manual tumor segmentation, which demands high time commitment and has inter-reader variability, can be replaced by an autosegmentation tool. The use of mpMRI and AI is projected to drive the field toward the personalized management of bladder cancer patients.

There is a need to develop user-friendly imaging tools estimating robust quantitative biomarkers (QIBs) from multiparametric (mp)MRI for clinical applications in oncology. Quantitative metrics derived from (mp)MRI can monitor and predict early responses to treatment, often prior to anatomical changes. We have developed a vendor-agnostic, flexible, and user-friendly MATLAB-based toolkit, MRI-Quantitative Analysis and Multiparametric Evaluation Routines (“MRI-QAMPER”, current release v3.0), for the estimation of quantitative metrics from dynamic contrast-enhanced (DCE) and multi-b value diffusion-weighted (DW) MR and MR relaxometry. MRI-QAMPER’s functionality includes generating numerical parametric maps from these methods reflecting tumor permeability, cellularity, and tissue morphology. MRI-QAMPER routines were validated using digital reference objects (DROs) for DCE and DW MRI, serving as initial approval stages in the National Cancer Institute Quantitative Imaging Network (NCI/QIN) software benchmark. MRI-QAMPER has participated in DCE and DW MRI Collaborative Challenge Projects (CCPs), which are key technical stages in the NCI/QIN benchmark. In a DCE CCP, QAMPER presented the best repeatability coefficient (RC = 0.56) across test–retest brain metastasis data, out of ten participating DCE software packages. In a DW CCP, QAMPER ranked among the top five (out of fourteen) tools with the highest area under the curve (AUC) for prostate cancer detection. This platform can seamlessly process mpMRI data from brain, head and neck, thyroid, prostate, pancreas, and bladder cancer. MRI-QAMPER prospectively analyzes dose de-escalation trial data for oropharyngeal cancer, which has earned it advanced NCI/QIN approval for expanded usage and applications in wider clinical trials.

Cancer care increasingly relies on imaging for patient management. The two most common cross-sectional imaging modalities in oncology are computed tomography (CT) and magnetic resonance imaging (MRI), which provide high-resolution anatomic and physiological imaging. Herewith is a summary of recent applications of rapidly advancing artificial intelligence (AI) in CT and MRI oncological imaging that addresses the benefits and challenges of the resultant opportunities with examples. Major challenges remain, such as how best to integrate AI developments into clinical radiology practice, the vigorous assessment of quantitative CT and MR imaging data accuracy, and reliability for clinical utility and research integrity in oncology. Such challenges necessitate an evaluation of the robustness of imaging biomarkers to be included in AI developments, a culture of data sharing, and the cooperation of knowledgeable academics with vendor scientists and companies operating in radiology and oncology fields. Herein, we will illustrate a few challenges and solutions of these efforts using novel methods for synthesizing different contrast modality images, auto-segmentation, and image reconstruction with examples from lung CT as well as abdome, pelvis, and head and neck MRI. The imaging community must embrace the need for quantitative CT and MRI metrics beyond lesion size measurement. AI methods for the extraction and longitudinal tracking of imaging metrics from registered lesions and understanding the tumor environment will be invaluable for interpreting disease status and treatment efficacy. This is an exciting time to work together to move the imaging field forward with narrow AI-specific tasks. New AI developments using CT and MRI datasets will be used to improve the personalized management of cancer patients.

The purpose of the present pilot study was to estimate T1 and T2 metric values derived simultaneously from a new, rapid Magnetic Resonance Fingerprinting (MRF) technique, as well as to assess their ability to characterize—brain metastases (BM) and normal-appearing brain tissues. Fourteen patients with BM underwent MRI, including prototype MRF, on a 3T scanner. In total, 108 measurements were analyzed: 42 from solid parts of BM’s (21 each on T1 and T2 maps) and 66 from normal-appearing brain tissue (11 ROIs each on T1 and T2 maps for gray matter [GM], white matter [WM], and cerebrospinal fluid [CSF]). The BM’s mean T1 and T2 values differed significantly from normal-appearing WM (p < 0.05). The mean T1 values from normal-appearing GM, WM, and CSF regions were 1205 ms, 840 ms, and 4233 ms, respectively. The mean T2 values were 108 ms, 78 ms, and 442 ms, respectively. The mean T1 and T2 values for untreated BM (n = 4) were 2035 ms and 168 ms, respectively. For treated BM (n = 17) the T1 and T2 values were 2163 ms and 141 ms, respectively. MRF technique appears to be a promising and rapid quantitative method for the characterization of free water content and tumor morphology in BMs.